- May 02, 2023Source: OncLive
Dr. Burtness on the Exploration of VIC1911 and Adavosertib in HNSCC and Lung Cancer
- January 11, 2023
Dr. Aarti Bhatia named Leader of the Head & Neck Disease-Aligned Research Team
- December 02, 2022
Barbara Burtness, MD, Named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital
- June 22, 2022Source: AACR
Comprehensive Viral Genotyping Reveals Prognostic Viral Phylogenetic Groups in HPV16-Associated Squamous Cell Carcinoma of the Oropharynx
- May 26, 2022Source: Oncotarget
New Tool Uses NF-κB Activity to Classify HPV+ Head and Neck Cancer
Yale Head and Neck Cancer Specialized Program of Research Excellence (SPORE)
Overcoming treatment resistance in Head and Neck Cancer
Yale Cancer Center was awarded a five-year, $11.7 million grant from the National Institutes of Health (NIH) to fund the Yale Head and Neck Cancer Specialized Program of Research Excellence (SPORE). The SPORE program harnesses the strengths of academic cancer centers by bringing together experts in oncology, immunobiology, pharmacology, molecular biology, pathology, epidemiology, and addiction science to collaborate on projects. The goal of the Yale Head and Neck Cancer SPORE (YHN-SPORE) is to address critical barriers to treatment of head and neck squamous cell carcinoma (HNSCC) due to resistance to immune, DNA damaging, and targeted therapy.
Projects
- The epidermal growth factor receptor (EGFR) remains the only validated molecular target in head and neck squamous cell carcinoma (HNSCC), mediating cell survival signaling and resistance to radiation therapy.
- HPV-negative head and neck squamous cell carcinomas (HNSCC) typically lose G1/S cell cycle checkpoints, with most tumors having mutations in TP53, and many also mutating other tumor suppressors such as CDKN2A.
- Human papillomavirus (HPV)-associated neck squamous cell carcinoma (HNSCC) represents an increasing proportion of HNSCC.